Product Name | 17-DMAG |
Description |
Hsp90 inhibitor |
Purity | >98% (TLC); NMR (Conforms) |
CAS No. | 467214-20-6 |
Molecular Formula | C32H48N4O8 |
Molecular Weight | 616.8 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO (30 mg/ml) and ethanol (10 mg/ml) |
Source | Synthetic |
Appearance | Purple Solid |
SMILES | C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)C)C)O)OC |
InChI | InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,( |
InChIKey | KUFRQPKVAWMTJO-LMZWQJSESA-N |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | 17-DMAG (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-114) |
Alternative Names | Alvespimycin, 17DMAG, 17-(dimethylaminoethylamino)-17-demethoxy-geldanamycin, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin, 17-desmethoxy-17-n,n-dimethylaminoethylamino-geldanamycin, 17-dimethylaminoethylamino-17-demethoxy-geldanamycin, 17-DMAG, 17-Dimethylaminoethylamino, 17-Demethoxygeldanamycin, [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-[2-(dimethylamino)ethylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate |
Research Areas | Cancer, Heat Shock |
PubChem ID | 5288674 |
Scientific Background | 17-DMAG is a water soluble & cell-permeable analog of Geldanamycin and 17-AAG (1). It binds to the APTase site of human Hsp90a with high affinity, has cytotoxic activity against many cancer cell lines (2), and acts as angiogenesis inhibitor (3). This Hsp90 inhibitor shows promise in preclinical models. 17-DMAG has excellent bioavailability, is widely distributed to tissues, and is quantitatively metabolized much less than is 17-AAG. |
References |
1. Bull E.E., et al.(2004) Clin. Cancer Res. 10: 8077. 2. Gossett D.R. et al.(2005) Gynecol. Oncol. 96: 381. 3. Kaur G. et al.(2004) Clin. Cancer Res. 10: 4813. |
Reviews
There are no reviews yet.